BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 23540866)

  • 1. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
    Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
    Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
    Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
    Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
    Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
    Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
    Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Tomizawa Y; Yoshino R; Yoshii A; Matsuura M; Iwasaki Y; Koga Y; Ono A; Nishioka M; Kamide Y; Hisada T; Ishizuka T; Shirai K; Ebara T; Saitoh J; Nakano T; Sunaga N
    Lung Cancer; 2013 Dec; 82(3):449-54. PubMed ID: 24099666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
    Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.
    Yamaguchi M; Toyokawa G; Ohba T; Sasaki T; Kometani T; Hamatake M; Hirai F; Taguchi K; Yamanaka T; Seto T; Takenoyama M; Sugio K; Ichinose Y
    Ann Thorac Surg; 2013 Nov; 96(5):1783-9. PubMed ID: 23998404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
    Nogami N; Takigawa N; Hotta K; Segawa Y; Kato Y; Kozuki T; Oze I; Kishino D; Aoe K; Ueoka H; Kuyama S; Harita S; Okada T; Hosokawa S; Inoue K; Gemba K; Shibayama T; Tabata M; Takemoto M; Kanazawa S; Tanimoto M; Kiura K
    Lung Cancer; 2015 Feb; 87(2):141-7. PubMed ID: 25534129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
    Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V
    Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
    Yoshimura N; Tada T; Matsumoto Y; Sawa K; Yoshimoto N; Suzumura T; Tanaka H; Mitsuoka S; Kimura T; Tamiya T; Hirashima T; Kawaguchi T; Kudoh S; Hosono M; Hirata K
    Am J Clin Oncol; 2018 Oct; 41(10):967-971. PubMed ID: 29045265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results.
    Hoppe BS; Flampouri S; Henderson RH; Pham D; Bajwa AA; D'Agostino H; Huh SN; Li Z; Mendenhall NP; Nichols RC
    Clin Lung Cancer; 2012 Sep; 13(5):352-8. PubMed ID: 22264659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
    J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.